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Abstract
Background. Chronic kidney disease (CKD) is a major
public health problem. In the UK, guidelines have been
developed to facilitate case identification and manage-
ment. Our aim was to estimate the annualized cost of
implementation of the guidelines on newly identified
CKD cases.
Methods. We interrogated the New Opportunities for
Early Renal Intervention by Computerised Assessment
(NEOERICA) database using a Java program created
to recompile the CKD guidelines into rule-based
decision trees. This categorized all patients with a
serum creatinine recorded over a 1-year period
into those requiring more tests or referral. A 12-
month cost analysis for following the guidelines was
performed.
Results. In the first year, a practice of 10 000 would
identify 147.5 patients with stages 3–5 CKD over and
above those already known. All stages 4–5 CKD cases
would require nephrology referral. Of those with stage
3 CKD (143.85), 126.27 stable patients would require
more tests. The following would require referral:
14.8 with estimated glomerular filtration rate decline
5ml/min/1.73m2/year, 1.11 with haemoglobin
<11 g/dl and 1.67 with blood pressure >150/90 on
three anti-hypertensives. The projected cost per prac-
tice of investigating stable stage 3 CKD was “ 6111;
and “ 7836 for nephrology referral. Total costs of
“ 17 133 in the first year were increased to “ 29 790
through the effect of creatinine calibration.
Conclusions. CKD guideline implementation results
in significant increases in nephrology referral and
additional investigation. These costs could be recouped
by delaying dialysis requirement by 1 year in one
individual per 10 000 patients managed according to
guidelines.
Keywords: cardiovascular risk; chronic kidney
disease; cost analysis; glomerular filtration rate;
guidelines; referral
Introduction
Chronic kidney disease (CKD) is a major public
health problem with significant health service costs,
compounded by the late referral to nephrology of
people with advanced renal disease. Current estimates
suggest that 5–11% of the total population have
CKD, defined as glomerular filtration rate (GFR)
<60ml/min/1.73m2 [1–5].
Not only are CKD patients at increased risk of
requiring renal replacement therapy (RRT) but also
have a significantly increased cardiovascular morbidity
and mortality [6]. Renal services currently consume
2% of the National Health Service (NHS) budget
in the UK [7] and this is set to rise with increasing
numbers requiring RRT. Tariff-based hospital
haemodialysis is expensive, costing “ 34 000 per patient
annually in the UK [8]. Late referral of patients from
both primary and secondary care to nephrology
services [9–11] results in increased hospitalization,
cost and mortality [12–15].
Late specialist referral of people with advanced
CKD is undesirable. Both the UK Renal National
Service Framework [16] and the inclusion of CKD in
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the financially incentivized quality-based contract for
general practice in England [17] reflects the increased
recognition of CKD within the NHS. More recently,
the Royal College of Physicians and Renal Association
have developed UK guidelines for the identification,
management and referral of people with CKD
(Table 1) [18,19]. These include comprehensive
guidance on the identification of CKD, appropriate
investigation, who should be monitored in the
community and who should be referred. We carried
out this study to determine the annualized cost of
implementing these guidelines on incident CKD cases.
Subjects and methods
Study population
The NEOERICA (New Opportunities for Early Renal
Intervention by Computerised Assessment) study is a large
community-based study of the comorbidity and medicines
management of a cohort of patients registered in primary
care in the UK. The study cohort comprised 162 113
participants of all ages and from 17 primary care practices
recruited from three regions: Kent, Surrey and Greater
Manchester. Data was extracted using Morbidity
Information Query and Export Syntax (MIQUEST) [20], a
Department of Health sponsored computer program, to
obtain read-coded data on these patients in the time period
1990–2003. Risk factors associated with CKD, comorbidity
and prescribed medication were obtained in addition to
demographic and biochemical results. Detailed descriptions
of the NEOERICA study design and objectives have been
published elsewhere [2]. The NEOERICA study, showed that
it is possible to identify CKD from routinely collected
general practice computers and also that these primary care
data are reliable [21].
Of the 162 113 participants, all adult patients (aged >18
years) who had a serum creatinine (SCr) measured over the
course of 1 year in the time period (1 July 2002 and 31 June
2003) were included for the purposes of the study. Estimated
GFR (eGFR) was calculated using the four-variable
Modification of Diet in Renal Disease (MDRD) study
formula [17]. Persons with no age recorded on the database
were excluded due to inability to calculate eGFR. Patients
already under the care of nephrology were excluded. In order
to ascertain the additional cost to be incurred in primary care
through implementing the CKD guidance, the remaining
patients were analysed further. For these patients, the
NEOERICA database was interrogated to determine existing
investigation results, comorbidity and prescription data.
Details of the data items used are listed in the description
of the computer simulation. This approach, therefore, only
identified new, incident CKD cases not already known to
nephrology during a 1-year period. Incident cases were
expressed as patients per 10 000 population.
Other epidemiological data used
Follow-up data [23] from the East Kent Longitudinal Study
of Unreferred CKD [24] were used to estimate the proportion
of patients with increased parathyroid hormone (PTH)
Table 1. Recommendations specified by the UK CKD Guidelines
Stage of CKD (GFR) Referral recommendation
Stage 5 (<15ml/min/1.73m2) Immediate referral
Stage 4 (15–29ml/min/1.73m2) Urgent referral (routine if known to be stable)
Stage 3 (30–59ml/min/1.73m2) Routine referral if:
 Progressive fall in GFR/increase in serum creatinine
 Microscopic haematuria present
 Urinary protein–creatinine ratio >100mg/mmol
 Unexplained anaemia (Hb< 11 g/dl), abnormal potassium, calcium or phosphate
 Suspected systemic illness, e.g. systemic lupus erythematosus
 Uncontrolled BP (>150/90mmHg despite complementary therapy with three classes
of antihypertensive agents)
Stage 1–2 (60–89ml/min/1.73m2) Referral not required unless other problems
Stage 1–2 (>60ml/min/1.73m2) Immediate referral for:
 Malignant hypertension




 Dipstick proteinuria present and urine protein/creatinine ratio >100mg/mmol
 Dipstick proteinuria and microscopic haematuria present
 Macroscopic haematuria but urological tests negative
Follow-up blood tests
Stage 3 CKD Annual potassium, creatinine and estimated GFR check, provided renal function is stable.
PTH concentration when stage 3 CKD is first diagnosed, and if raised, test 25-hydroxy vitamin D.
Stage 4/5 CKD Three monthly check: FBC, renal function. PTH as above
Renal ultrasound
Any CKD stage Patients with lower urinary tract symptoms
Uncontrolled hypertension
Family history of hereditary renal disease
Unexplained fall in GFR
CKD, Chronic kidney disease; GFR, Glomerular filtration rate; Hb, haemoglobin; PTH, parathyroid hormone; FBC, full blood count.
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concentration. In this study, CKD patients were defined
using the National Institute of Health referral criteria
(SCr> 80 mmol/l in males and >135 mmol/l in females)
yielding a prevalence of CKD (median eGFR 28.5ml/min/
1.73m2) of 5554 per million population: 84.8% of patients
were unknown to the renal service. During a median
follow-up of 31 months, 38% had died due to cardiovascular
disease with renal failure accounting for only 5% of the
deaths. A subset of unreferred patients was studied
prospectively to examine the potential benefit of specialist
investigation and management. The majority of patients
had stable CKD, only 2.8% had an eGFR declining by
5ml/min/1.73m2/year. More than one-third (37%) of CKD
patients had increased PTH concentrations (90 ng/l).
Computer simulation
A computer program was written using Java (Sun
Microsystems) to simulate implementing the CKD guide-
lines. This program contained 30 pages of Java source code
and recompiled the guidelines in the form of rule-based
decision trees. The program parsed the NEOERICA data
carrying out the following steps:
(i) All adults with a SCr result in the study entry period
were identified, i.e. the SCr must lie between 1 July
2002 and 31 June 2003.
(ii) Previous SCr values prior to the study entry period on
the new cases identified in step (i) were highlighted.
(iii) GFR for all SCr results were calculated using the four-
variable MDRD formula.
(iv) Where more than one SCr recording was present, rate
of change in eGFR was ascertained.
(v) New (incident) cases of CKD were defined as those
with a newly identified eGFR <60ml/min/1.73m2
within the 1-year study entry period. Those with any
history of a renal diagnosis, procedure or referral to a
nephrologist were presumed to be existing (prevalent)
cases and were excluded.
(vi) The incident cases were further divided into those with
abnormal results or rate of decline requiring nephrol-
ogy referral and those with stable renal disease
requiring further blood tests that had not been done
previously.
(vii) The following factors were identified by the program to
enable it to model whether further investigation or
referral of incident cases might be indicated: systolic
blood pressure (BP), diastolic BP, prescription of anti-
hypertensive medication, in addition to laboratory
investigations (SCr, haemoglobin (Hb), potassium,
calcium, phosphate, 25-hydroxy vitamin D and PTH).
(viii) Uncontrolled hypertension was defined as an incident
patient with a BP >150/90mmHg while on three
complementary groups of anti-hypertensive agents.
(ix) Unacceptably declining renal function was defined as a
rate of decline of eGFR 5ml/min/1.73m2/year.
Calculation of cost
(i) For cost calculation, items recommended in the UK
CKD guidelines were priced using the 2004 national
schedule of reference costs [8].
(ii) All costs were calculated for the following year
on identified incident cases using a pragmatic
cost model.
Total cost ¼ Cost of initial investigationsþ referral cost
þ follow-up cost
Where,
Initial investigation costs ¼ Initial laboratory cost
þ ultrasound cost
Referral costs ¼ Initial nephrology referral cost
þ follow-up nephrology visit
costs over 12 months
Follow-up cost ¼ Follow-up laboratory
investigation cost over
12 months
(iii) Only costs of any additional investigations required to
complete the list dictated in the guidelines were added.
Other tests were not repeated, except where the
guidelines required confirmatory tests prior to possible
referral; e.g. repeat SCr when eGFR is rapidly
declining or where there was only a single SCr
recorded.
(iv) Costs were converted from British pounds (GBP) to
EUR using a currency conversion rate of 1.48. Given
that the average population of a primary care practice
in the UK is 10 000 patients, costs were expressed per
10 000 patients.
(v) A sensitivity analysis was conducted to systematically
examine the influence of variation in the variables used
for the cost calculation.
Sensitivity analysis
First, the change in prevalence engendered by creatinine
calibration was modelled into the sensitivity analysis. We
have shown that SCr calibration to the method used by the
MDRD laboratory in the NEOERICA database increased
the proportion of stage 3 CKD by a factor of 1.75 and stage
4 CKD by a factor of 1.6, while stage 5 CKD remained
unaffected [25]. This increase in detected prevalence would
increase the cost.
Second, data was used from a manual search of
500 records [21]; and examining the change in prevalence of
CKD recording in the same practice, e.g. a higher detection
of incident CKD would result in higher cost prediction.
Third, the cost-lowering effect if a higher proportion of
patients were already known to nephrology was also assessed.
Lastly, other population studies [26–29] show higher
prevalence rates for lower urinary tract symptoms (LUTS);
and this too was factored into the sensitivity analysis when
taking into account renal ultrasound costs.
Assumptions made
The following assumptions were made in the calculation of
the cost model:
(i) All patients with a specific nephrology read-code
diagnosis were assumed to be already under
nephrology follow-up.
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(ii) All patients with unacceptably declining renal function
were assumed to require referral to nephrology
services.
(iii) All at-risk stage 3 CKD persons (unacceptably
declining renal function, Hb <11 g/dl and uncontrolled
hypertension) would be referred to nephrology,
thereafter followed up in primary care.
(iv) A renal tract ultrasound would be performed on all
11% of the stage 3 CKD population with LUTS.
Similarly, ultrasonography would be performed on
all patients with uncontrolled hypertension and
unacceptably declining renal function prior to referral.
(v) For PTH-related cost, it was assumed that 37% of
persons with CKD would have increased PTH
(90 ng/l) using data from the follow-up study [23] to
the East Kent Longitudinal study [24].
(vi) All stage 4 and 5 CKD were suitable for nephrology
assessment and would be followed up by nephrology.
(vii) Patients requiring nephrology follow-up would be seen
three times in the next 12 months.
Results
In the 1-year time period, 13 862 adult patients with an
SCr were identified by the Java simulation (Figure 1).
Of these, 1227 patients were already under the care of
nephrology and 450 patients had no age recorded for
eGFR calculation. 9794 of the remaining 12 185 had an
eGFR 60ml/min/1.73m2, leaving 2391 patients high-
lighted to have CKD (eGFR <60ml/min/1.73m2).
This equates to 147.5 patients per 10 000 population.
Of the 147.5 per 10 000 with eGFR<
60ml/min/1.73m2 identified in the first year, 3.34 and
0.31 per 10 000 would have stage 4 and 5 CKD,
respectively and 143.85 patients per 10 000 would have
stage 3 CKD. A small proportion of stage 3 patients
would require referral to nephrology: 1.11 per 10 000
with Hb <11 g/dl, 1.67 per 10 000 with uncontrolled
hypertension and 14.8 per 10 000 with unacceptably
declining renal function. The remainder (126.27 per
10 000) would have stable stage 3 CKD and not require
referral; instead, they would need to undergo ‘catch up’
laboratory investigations to comply with the guide-
lines. All stages 4 and 5 CKD patients would require
referral.
Table 4 shows the combinations of initial ‘catch up’
laboratory investigations that would be required on
stage 3 CKD individuals. These tests were based upon
missing investigations encountered by the Java simula-
tion i.e. tests not already performed by primary care.
The majority of the additional initial tests required for
people with stage 3 CKD would be an additional SCr
measurement to confirm the diagnosis, in addition to
renal bone disease investigations amounting to a total
of “ 3145 per practice. Included in this cost is an initial
test for PTH concentration, recommended by the
guidelines on all stage 3 CKD patients. Adding the
confirmatory test for eGFR in CKD stage 3 patients
with declining renal function and those with a single
eGFR showing stage 4 CKD, the total initial blood test
investigation cost would be “ 3197 per practice. Renal
ultrasound costs were “ 2914 (Table 3).
Approximately, half of the ultrasound cost was for
patients with declining renal function (“ 1421), most of
the remainder was for investigation of LUTS (“ 1333)
and “ 160 was for individuals with uncontrolled
hypertension.
The total referral cost was “ 7836 per 10 000
(Table 3); “ 6008 for the first visit and “ 1828 for
follow-up visits. A large proportion of this cost (“
4188) was for referral of the 14 patients with declining
renal function. The initial out-patient referral cost of
the two to three new cases with stage 4 CKD amounted
to a cost of “ 784þ 158, while a new stage 5 CKD out-
patient referral would cost “ 88 per 10 000 per year.
Assuming that all new cases of stage 4 and 5 CKD
remained under long-term nephrology follow-up and
were seen three times in the next 12 months, primary
care would incur a cost of “ 1828 just to support out-
patient follow-up.
Table 5 shows the breakdown of follow-up labora-
tory investigations required in the next 12 months.
Practices would be required to monitor the 126.27
patients per 10 000 with stable stage 3 CKD with an
annual eGFR, electrolytes and full blood count
investigation. Patients at higher risk (uncontrolled
hypertension, Hb <11 g/dl and unacceptably declining
renal function) would require at least two monitoring
tests in the next year. The total cost of follow-up blood
tests was “ 3186 per practice. Given that testing for
PTH and 25-hydroxy vitamin D is expensive, that
would account for two-thirds of the cost (“ 2056 per
practice).
The final cost estimation per practice in the first
year was:
Total cost ¼ Cost of initial investigations
þ total referral costþ follow-up cost
¼ “ 6111þ “ 7836þ “ 3186
¼ “ 17 133 per practice of
10 000 patients
Sensitivity analysis
The impact of the sensitivity analysis is described in
detail in Table 6. The effect of calibration of creatinine
was to lower eGFR and this effect was greatest at
lower creatinine levels. The proportion of those with
stage 5 CKD remained unchanged, whilst the propor-
tion of those with stage 4 CKD increased by a factor of
1.6, and by a factor of 1.75 in people with stage 3
CKD. The impact of including creatinine calibration
into the sensitivity analysis significantly increased cost.
Based upon a detailed review of primary care
practices, the annual audits of CKD revealed that the
proportion of the patient population who have had a
SCr measured has risen from 2522 (23%) in 2004; to
3013 (27%) in 2005; and to 3565 (32%) in data
collected for 2006. The prevalence of identified CKD
has risen to 6.4% (709/1140) in 2006 compared with
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the 5.1% in 2004. There has been little change in BP.
Between 2004 and 2005, mean systolic BP fell from
143.4 to 140.7mmHg (P< 0.001); and then increased
to 141mmHg in 2006. Diastolic BP steadily reduced
from 80.7 to 79.9, and then to 79.2mmHg across the
3 years of the audit.
A systematic review of one of the practices used in
the NEOERICA study that showed that the computer
search underestimated the number of patients known
to renal services by 11% (4/36) compared with the
manual search.
Variations in the prevalence rates for LUTS exist:
three other large population studies showed different








1 Jan 1990–31 June 2002
Search for previous SCr and other information
on highlighted patients.
Incident cases:
(Stage 3-5 CKD only)
Patients not known to nephrology
n = 2,391











mmHg, on three antihypertensive
agents):
1.67 patients per 10000 population
Anaemic (Hb <11g/dL):
1.11 patients per 10000 population
Stable patients and single GFR reading:
126.27 patients per 10000 population
Declining GFR ≥ 5mL/min/1.73 
m2/year:
14.8 patients per 10000 population
Single GFR reading:
2.78 patients per 10000 population
Stable Stage 4 CKD:
0.56 patients per 10000 population
Patients excluded:
⋅ n =1,227; known to nephrology (prevalent cases)
⋅ n =450; age not recorded, cannot calculate eGFR











Fig. 1. Patients grouped by the Java simulation. aPatients per 10 000¼ (10 000 2391)/162 113.





1,25-hydroxy vitamin Da 22
Haematology, excluding anti-coagulation 4
Ultrasound renal tract 96
Nephrology out-patient (first visit) 283
Nephrology out-patient (follow-up) 167
aKent and Medway reference cost.
Figures rounded to nearest EUR; for conversion from EUR to USD,
multiply by 1.45; for EUR to GBP multiply by 0.67.
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for LUTS in men older than 40–45 years of age and a
study by Terai et al. [29], shows prevalence rates for
LUTS to be similar in both genders. The prevalence of
LUTS at 11% in NEOERICA may, therefore, have
been an underestimation; rather, a mean of the above
population studies (20%) would probably be a more
realistic estimation.
Re-running the model on the basis of creatinine
calibration, an 11% increase in the proportion of
patients known to renal services, the growth in SCr
concentration recording (and indirectly the CKD pre-
valence by 1.3%), little change in systolic BP control
and increased prevalence of LUTS (20%), the model
produced a maximum estimate of “ 29 270 per practice.
Discussion
This study provides an estimate of workload and cost
in the first 12 months of implementing the new UK
guidelines for the management of newly identified
CKD cases over a 1-year period. In interpreting
the results, it is important to realize that the study
concentrates on ‘incident’ stages 3–5 CKD, not
‘prevalent’ CKD. The cost of implementation of



















Stage 3 Stable stage 3
(includes single GFR
reading)
126.27 3145 1333a 3145 – –
Anaemic
(Hb< 11 g/dl)
1.11 – – 16 314 –
Uncontrolled
hypertension
1.67 – 160 23 473 –
Declining GFR
5ml/min/1.73m2/year
14.8 44 1421 207 4188 –
Stage 4 Single GFR
reading
2.78 8 – – 787 1392
Stable Stage 4 CKD 0.56 – – – 158 281
Stage 5 0.31 – – – 88 155
Subtotal 3197 2914 3186 6008 1828
6111 “ 3186 “ 7836 “
Total cost per 10 000 population 17 133 “
Figures rounded to nearest EUR, for conversion from EUR to USD, multiply by 1.45; for EUR to GBP multiply by 0.67.
Cost per cell: multiply corresponding amount of patients by unit cost for investigation or referral (Table 2).
aAssumption 4.
bAssumption 6.
Table 4. The cost of initial laboratory investigations required on newly identified CKD cases
Newly identified cases Combinations of new
tests required
Patients per 10 000
population
Cost (per 10 000 population)
Stable stage 3 CKD












PTH only 3.35 74
(Subtotal 3145 “)
Stage 3 CKD, declining
GFR 5ml/min/1.73m2/year
Repeat GFR 14.8 44
Stage 4 CKD,
single GFR reading
Repeat GFR 2.78 8
Total cost 3197 “
Figures rounded to nearest EUR, for conversion from EUR to USD, multiply by 1.45; for EUR to GBP multiply by 0.67.
Cost per cell: multiply corresponding amount of patients by unit cost for investigation (Table 2).
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these guidelines has three components: First, there is a
cost of referral to secondary care. Second, a cost of
‘catch-up’ investigations; and lastly, the cost of
ongoing monitoring of stable CKD patients.
The guidelines, designed to reduce late referral of
stages 4 and 5 CKD and high-risk cases, will in the
short-term accelerate the number of patients being
referred to secondary care. Although this will result in
an increased workload for nephrology, patients may
benefit through earlier reduction of cardiovascular
risk, treatment of anaemia and patient education.
The costs of implementation of the guidelines may be
offset in the long-term by the reduction in number of
people progressing to require RRT, and by a reduction
in late referral for dialysis. These benefits, however,
cannot currently be incorporated in a cost-savings
model because, as yet, there are no outcome data
on early referral and reduction of development of
end-stage renal disease (ESRD). This also holds true
for the increased expenditure required on ‘catch-up’
investigations and ongoing monitoring of stable CKD
patients. The majority of extra investigations were
found to be tests related to renal bone disease
parameters (calcium, phosphate and PTH). Currently
due to the lack of outcome data on the monitoring of
renal bone disease, the benefits of testing for these
parameters are debateable. The UK CKD guidelines
acknowledge the high costs associated with this
strategy and that currently there is only limited
outcome data demonstrating benefit as a result of
this increased testing [30]. However, it is also acknowl-
edged that the recommendations are far less extensive
in this respect than those in other comparable
international guidelines [31,32]. Commissioners of
NHS services will have to carefully appraise the
cost–benefit of carrying out these tests.
The volume of work the guidelines will create in
general practice will not be dissimilar to volume of
work in other areas of chronic disease management
with a similar prevalence; for example cholesterol
management in cardiovascular disease. General
practice has shown itself to be equal to the challenge
of quality improvement in this field [33,34]. This has
been achieved through audit as well as more
recently through financially incentivised quality
improvement [17,35].
The study clearly has limitations. Firstly, figures are
based upon the detection of newly identified cases in
one calendar year and the numbers of incident CKD
cases are, therefore, dependant on the amount of
persons tested for SCr in the study period. More
specific screening approaches [36], where restriction of
Table 5. The cost of follow-up laboratory investigations in next 12 months
Newly identified cases




Stable CKD stage 3 126.27 Potassium, creatinine,
estimated GFR; Full blood count checked once
884
25-hydroxy vitamin DþPTH checked once 2056a
Anaemia (Hb< 11 g/dl) 1.11 Potassium, creatinine,
estimated GFR; Full blood count
checked twice
16
Uncontrolled hypertension 1.67 23
Declining GFR 5ml/min/1.73m2/year 14.8 207
Total cost 3186 “
Figures rounded to nearest EUR, for conversion from EUR to USD, multiply by 1.45; for EUR to GBP multiply by 0.67.
Cost per cell: multiply corresponding amount of patients by unit cost for investigation (Table 2).
aAssumption 5.
Table 6. Sensitivity analysis
Cost breakdown Current calculation Analysis1 Analysis 2 Analysis 3 Analysis 4
Initial blood tests 3197 5593 5666 5043 5043
Ultrasound 2914 5100 4167 4598 6320
Initial referral 6008 10 307 10 441 9292 9292
Follow-up blood tests 3186 5575 5674 5026 5026
Follow-up referral 1828 2833 2869 2554 2554
Total per 10 000 patients 17 133 “ 29 408 “ 29 790 “ 26 513 “ 28 235 “
All figures rounded to nearest EUR, for conversion from EUR to USD, multiply by 1.45, for EUR to GBP multiply by 0.67.
Analysis 1: Increase in stage 4 CKD by a factor of 1.6 and stage 3 CKD by a factor of 1.75 due to calibration of SCr.
Analysis 2: Analysis 1 plus increase in CKD incidence by 1.3% due to increased testing for SCr.
Analysis 3: Analysis 2 plus an increase in known-to-nephrology (prevalent) cases by 11%.
Analysis 4: Analysis 3 plus an increase in LUTS prevalence to 20%.
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screening to those with hypertension, diabetes or
aged older than 55 years would, according to
Hallan et al., [36] potentially identify more people
with CKD and carry a significantly greater cost.
Nevertheless, the NEOERICA data was representative
of the diversity of comorbidity. in all people registered
in primary care and a substantial sample of day-to-day
CKD management in primary care practice was
available. Recorded data in high-risk patients was
high, thus enabling a reasonable cost estimation for
primary care. A recorded sCr was available in 27% of
the NEOERICA population and 46.3% had two or
more sCr values greater than three months apart.
We found that recording of sCr in patients with
diabetes mellitus was 83.6%, suggesting that targeted
testing for CKD is already occurring in primary care in
the UK. Therefore, our projected costs produced by
the model are likely to be reasonably accurate.
The NEOERICA data was collected before the
inception of the new primary care general practitioner
contract [17,35]. This contract provides financial
incentives for the creation of registers for certain
chronic diseases (hypertension, diabetes and CKD
since 2006) and is bound to have had a positive effect
on increased testing for renal disease in such high risk
populations. The effect of increased detection of
incident cases of CKD through increased testing
for SCr has been included in the sensitivity analysis.
This gives some indication of the possible accuracy of
the cost estimate, and costs may change as more
research is carried out in this domain. Also, within the
sensitivity analysis, we have modelled for the impact of
SCr calibration on stage of CKD. This significantly
increased the total cost from “ 17 133 to “ 29 408 per
10 000 patients
We have not modelled for the mortality from CKD.
Keith et al. [37] found 5-year mortality rates in CKD as
high as 24.3% in stage 3 CKD patients. For the costs
model, we included patients who were more likely to be
alive i.e. had had a blood test for SCr in the latter
one year of the database. Moreover, to further mini-
mize the effect of mortality, only costs for the initial
12 months of following the guidelines were modelled.
We did not include the cost of any of the additional
therapy that might be generated from the investigation
of the patients highlighted for referral. Likewise, we
have made no estimate of the costs of tertiary referral
in secondary care for the management of any
comorbidities or underlying diagnoses identified.
We have not included the costs of treatment of any
renal anaemia detected.
We also acknowledge that some stages 4 and 5 CKD
cases may have been unsuitable for nephrology
referral due to excessive comorbidity. Conversely,
had proteinuria data been present we could have
included it in the model. Proteinuria is often recorded
in free text in primary care so the decision tree(s) were
therefore unable to provide categorization information
on patients with overt proteinuria due to the poor data
quality in this area in general practice computer
systems.
Conclusion
CKD has been largely unrecognized in UK primary
care. The combination of the UK Renal National
Service Framework, the inclusion of CKD in
the quality-based primary care general practitioner
contract, implementation of eGFR reporting and the
UK guidelines have raised awareness of CKD.
The new CKD guidelines represent the creation of a
more specific platform of care for patients with CKD.
Undoubtedly, they would result in increased referral of
stages 4 and 5 and high-risk stage 3 CKD, and this has
potential to reduce morbidity and mortality in these
patients. In order to comply with the guidelines, much
more routine testing of CKD parameters, particularly
those of renal bone disease would be required. It is
evident that there will be an increased financial
resource required to deliver an effective CKD manage-
ment programme: the cost of initial management of
newly identified CKD in one year for a practice of
10 000 being between “ 17 113 and “ 29 790. In terms
of the actual budget of a primary care practice, this
may seem an acceptable cost considering the high
prevalence of CKD. As yet it is uncertain whether
following the guidelines will have a significant effect on
hard outcomes of CKD, such as rate of progression
and reduction of cardiovascular disease and a reduc-
tion in ESRD. The benefit alone of reduction of late
referral may not justify the estimated cost of “ 17 133–
“ 29 790. However, this strategy only has to delay
ESRD by a single year on one patient to save “ 34 000.
Will the increased cost be offset by a reduction of
ESRD or cardiovascular comorbidity? This will have
to be the focus of future research.
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